Barclays PLC Alkermes Plc. Transaction History
Barclays PLC
- $436 Billion
- Q2 2025
A detailed history of Barclays PLC transactions in Alkermes Plc. stock. As of the latest transaction made, Barclays PLC holds 694,122 shares of ALKS stock, worth $19 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
694,122
Previous 694,122
-0.0%
Holding current value
$19 Million
Previous $19.9 Million
-0.0%
% of portfolio
0.0%
Previous 0.01%
Shares
32 transactions
Others Institutions Holding ALKS
# of Institutions
394Shares Held
176MCall Options Held
558KPut Options Held
427K-
Black Rock Inc. New York, NY29.1MShares$796 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.5MShares$506 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD10MShares$275 Million0.03% of portfolio
-
State Street Corp Boston, MA8.21MShares$225 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY6.41MShares$175 Million1.86% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.49B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...